Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin PharmaThe SP16 Phase 1b trial ...
All-Stock Licensing Deal for Treatment of Cancer Related Pain On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 ...
ATLANTA, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a clinical-stage biotechnology company developing new medicines to treat pain and ...
7d
Dogwood Therapeutics, Inc. (DWTX) Advances SP16 Program with FDA Investigational New Drug Approval
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Dogwood Therapeutics, Inc. is one of the oversold biotech stocks on this list. TheFly reported on April 15 that DWTX ...
SP16 is an investigational intravenous therapy designed to treat chemotherapy-induced pain and peripheral neuropathy, also ...
(RTTNews) - Dogwood Therapeutics, Inc. (DWTX) said, in an all-stock transaction, it has secured a royalty free, global license to develop Serpin Pharma's intravenous formulation of SP16 to manage ...
Serpin Pharma receives FDA IND approval for SP16, a novel therapy for chemotherapy-induced peripheral neuropathy. Phase ...
The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia “FDA acceptance of our SP16 IND ...
We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Dogwood Therapeutics, Inc. is one of the oversold biotech stocks on this list. TheFly reported on April 15 that DWTX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results